Cabaletta Bio, INC Form 4 insider transactions

Director Shawn Tomasello was granted 22,000 stock options in Cabaletta Bio, Inc. as part of standard equity compensation.

Director Mark Simon was granted 22,000 stock options in Cabaletta Bio, Inc. as part of standard equity compensation.

Director Richard C. Henriques Jr. was granted 22,000 stock options in Cabaletta Bio, Inc. as part of standard equity compensation.

Director Catherine Bollard was granted 22,000 stock options in Cabaletta Bio, Inc. as part of standard equity compensation.

Director Scott C. Brun was granted 22,000 stock options in Cabaletta Bio, Inc. as part of standard equity compensation.

Cabaletta Bio's Chief Business Officer, Arun Das, was granted 175,000 stock options with a $3.3 exercise price, vesting over several years.

Cabaletta Bio's General Counsel, Michael Gerard, was granted 175,000 stock options with an exercise price of $3.30 per share.

Cabaletta Bio's President of Science & Technology, Gwendolyn Binder, was granted 225,000 stock options with a future vesting schedule.

Cabaletta Bio's Chief Medical Officer, David J. Chang, was granted 225,000 stock options with an exercise price of $3.30, vesting over four years.

Cabaletta Bio's President and CEO, Steven Nichtberger, was granted 674,000 stock options with a $3.3 exercise price and a multi-year vesting schedule.

Cabaletta Bio's Chief Financial Officer, Anup Marda, was granted 225,000 stock options with an exercise price of $3.30, vesting over several years.

Cabaletta Bio's Chief Medical Officer, David J. Chang, reported a planned acquisition of 8,800 shares of common stock at $2.26 per share, effective January 21, 2026.

Cabaletta Bio's President of Science & Technology, Gwendolyn Binder, acquired 11,312 shares of common stock at $2.1891 per share.

Cabaletta Bio Director Shawn Tomasello plans to acquire 22,725 shares of common stock indirectly through Shawn Tomasello Consulting LLC at a price of $2.2144 per share on January 21, 2026.

Cabaletta Bio's Chief Commercial Officer, Steve Gavel, reported the purchase of 22,170 shares of common stock at a weighted average price of $2.265.

Cabaletta Bio Director Catherine Bollard plans to acquire 4,405 shares of common stock on January 21, 2026, under a Rule 10b5-1 trading plan.

Cabaletta Bio's President and CEO, Steven Nichtberger, acquired 45,000 shares of common stock at a weighted average price of $2.2395, signaling increased insider confidence.

Cabaletta Bio, Inc. Director Mark Simon acquired 11,061 shares of common stock at a weighted average price of $2.2838 per share.

Cabaletta Bio's General Counsel, Michael Gerard, has filed to purchase 6,600 shares of common stock on January 21, 2026, at a weighted average price of $2.2696 per share.

Cabaletta Bio, Inc. granted 275,000 stock options to its new Chief Commercial Officer, Steve Gavel, as an inducement for his employment.

Cabaletta Bio, Inc. Director Mark Simon was granted 22,000 stock options with an exercise price of $2.37, vesting by June 2026 or the next annual meeting.

Cabaletta Bio, Inc. Director Scott C. Brun was granted 22,000 stock options with an exercise price of $2.37, vesting upon the earlier of June 9, 2026, or the next annual stockholders' meeting.

Cabaletta Bio, Inc. Director Catherine Bollard was granted 22,000 stock options with an exercise price of $2.37, set to vest by June 2026 or the next annual stockholders' meeting.

Cabaletta Bio, Inc. Director Shawn Tomasello was granted 22,000 stock options with an exercise price of $2.37, aligning his interests with shareholder value.

Richard C. Henriques Jr., a Director at Cabaletta Bio, Inc., was granted 22,000 stock options with an exercise price of $2.37, set to vest by June 2026 or the next annual meeting.

Scott C. Brun, a director at Cabaletta Bio, Inc., had stock options repriced on May 19, 2025, according to a Form 4 filing with the SEC.

Cabaletta Bio's CEO, Steven Nichtberger, had his stock options repriced by the company's board of directors, effective May 19, 2025.

Michael Gerard, General Counsel of Cabaletta Bio, receives repriced stock options following board approval.

Richard C. Henriques Jr., a director at Cabaletta Bio, Inc., received repriced stock options on May 19, 2025, as part of an option repricing approved by the board.

Director Shawn Tomasello receives repriced stock options from Cabaletta Bio, Inc. following board approval.